44 THE INERANJOURNAL OF PEDIATRICS 1996; Vol. 63. No. 1 Livingsttme, 1992; 161-169. 3. Louis IL. Outpatient Evaluation and Management of Asthma. PCNA 1979; 26 : 581-601. 4. David' AS~, ' Gregory JR. Management of Acute Asthma. PCNA 1992; 39 : 1211- 1325. 5. Benton G, Thomas RC, Nicketson EG etaJ. Experience with a metered-dose inhaler with a spacer in the pediatric.emergency depa~tu,ent. Am ] Dis Child .!989; 143 : 678-681. 6. Bierman CW, Pearlman DS. Astir. In : Victor C. & Edwin LK eds. Kendig's Disorders of the Respiratory "tract in children. 5th ed Philadelphia : W.B. Saunders company, 1990 : 557-600. 7. Asher T, Nisaim L, Jacob EB. Methylpred- nisolone therapy for acute asthma in infants and toddlers : A controlled clinical trial. Ped/atr/cs 1990; 86 : 350-335. 8. Greos I..S, Vichyanond P, Bloedow DC et al. Methylprednisolone achieves greater concentrations in the tung than prednisolone. S Am Rev Respir Dis 1991; 144 : 586-592. 9. Shah MD & Lahiri KR. Pulmonary function testing in office practice. Indian Pediatrics 1992; 29 : 387-393. 10. Janice HH, Thomas, Colleen LL. Patient education. PCNA 1992; 39.: 1343-1361. 11. David As, Stanley JS. Management of chronic asthma. PCNA 1992; 39 : 1293- 1309. ACELLUI~ PERTUSS!SVACCINESAFE Acelluar pcrtu~is vaccine is safe, r and more effective than whole-cell vaccine in two, four and six-month-old infants, according to two clinical trials by thefederal government. The trials, conducted in Italy and Sweden involving more than 25,000 children, revealed that the acellular perl~sis vaccine produced fewer minor side effects, such as fever and local reactions, thah the whole-cell pertuMs vaccine currently used. ~Tirke acellular vaccbies in the study were determined ~ be roughly 85 percent effective, conMdorably higher than the efficacy rate Of ~e whole-cell vaccine used in bo~h trtals. ~u vaccines currently in use have been reported to be 70 io 95 percent effective. The real good news about this isn't the ~icacy. With these new vaccines, there are far fewer side effects, and parents would be nugre likely to immunize their childre~ Annually, perfussis affects more than 50 million peop4e worM-wide, primarily infants, resulting in roughly 350,O00deaths. Abstracted from : Leigh Ann Bluestein and Gerry Clark, AAP News, August 1995 page 8-9.

Acellular pertussis vaccine safe

Download PDF Report

View
219
Download
0

Embed Size (px)

Citation preview

Page 1: Acellular pertussis vaccine safe

44 THE INERAN JOURNAL OF PEDIATRICS 1996; Vol. 63. No. 1

Livingsttme, 1992; 161-169. 3. Louis IL. Outpatient Evaluation and

Management of Asthma. PCNA 1979; 26 : 581-601.

4. David' AS~, ' Gregory JR. Management of Acute Asthma. PCNA 1992; 39 : 1211- 1325.

5. Benton G, Thomas RC, Nicketson EG etaJ. Experience with a metered-dose inhaler with a spacer in the pediatric.emergency depa~tu,ent. Am ] Dis Child .!989; 143 : 678-681.

6. Bierman CW, Pearlman DS. A s t i r . In : Victor C. & Edwin LK eds. Kendig's Disorders of the Respiratory "tract in children. 5th ed Philadelphia : W.B. Saunders company, 1990 : 557-600.

7. Asher T, Nisaim L, Jacob EB. Methylpred- nisolone therapy for acute asthma in infants and toddlers : A controlled clinical trial. Ped/atr/cs 1990; 86 : 350-335.

8. Greos I..S, Vichyanond P, Bloedow DC et al. Methylprednisolone achieves greater concentrations in the tung than prednisolone. S Am Rev Respir Dis 1991; 144 : 586-592.

9. Shah MD & Lahiri KR. Pulmonary function testing in office practice. Indian Pediatrics 1992; 29 : 387-393.

10. Janice HH, Thomas, Colleen LL. Patient education. PCNA 1992; 39.: 1343-1361.

11. David As, Stanley JS. Management of chronic asthma. PCNA 1992; 39 : 1293- 1309.

ACELLUI~ PERTUSS!S VACCINE SAFE

Acelluar pcrtu~is vaccine is safe, r and more effective than whole-cell vaccine in two, four and six-month-old infants, according to two clinical trials by thefederal government. The trials, conducted in Italy and Sweden involving more than 25,000 children, revealed that the acellular perl~sis vaccine produced fewer minor side effects, such as fever and local reactions, thah the whole-cell pertuMs vaccine currently used. ~Tirke acellular vaccbies in the study were determined ~ be roughly 85 percent effective, conMdorably higher than the efficacy rate Of ~e whole-cell vaccine used in bo~h trtals. ~u vaccines currently in use have been reported to be 70 io 95 percent effective. The real good news about this isn't the ~icacy. With these new vaccines, there are far fewer side effects, and parents would be nugre likely to immunize their childre~ Annually, perfussis affects more than 50 million peop4e worM-wide, primarily infants, resulting in roughly 350,O00deaths.

Abstracted from : Leigh Ann Bluestein and Gerry Clark, AAP News, August 1995 page 8-9.